The following is a summary of the terms of the notes offered by the preliminary pricing supplement hyperlinked below.
Summary of Terms
Issuer:
JPMorgan Chase Financial Company LLC
Guarantor:
JPMorgan Chase & Co.
Minimum Denomination:
Denomination:$1,000
Underlyings:
Nikkei 225 Index (the “Index”) and iShares ® MSCI Emerging Markets ETF (the “Fund”)
Pricing Date:
March 31, 2021
Observation Date:
March 30, 2026
Maturity Date:
April 2, 2026
Upside Leverage Factor:
At least 2.10*
Barrier Amount:
With respect to each Underlying, 70.00 % of its Initial Value
Payment At Maturity:
If the Final Value of each Underlying is greater than its Initial Value, your payment at maturity per
$1,000 principal amount note will be calculated as
$1,000 + ($1,000
×Lesser Performing Underlying Return ×Upside Leverage Factor)
If the Final Value of
either Underlying is equal to or less than its Initial Value but the Final Value of
each Underlying is greater than or equal to its Barrier Amount, you will receive the principal amount
of your notes at maturity.
If the Final Value of
either Underlying is less than its Barrier Amount, your payment at maturity per
$1,000 principal amount note will be calculated as follows
$1,000 +
1,000 ×Lesser Performing Underlying Return)
If the Final Value of
either Underlying is less than its Barrier Amount, you will lose more than
30.00 % of your principal amount at maturity and could lose all of your principal amount at
CUSIP:
48132RR77
Preliminary Pricing
Supplement:
http://sp.jpmorgan.com/document/cusip/48132RR77/doctype/Product_Termsheet/document.pdf
For more information about the estimated value of the notes, which likely will be lower than the price you paid for the notes
, p lease see the hyperlink above.
Any
payment on the notes is subject to the credit risk of JPMorgan Chase Financial Company LLC, as issuer of the notes, and the credit
risk of JPMorgan Chase & Co., as guarantor of the notes
* The actual
Upside Leverage Factor will be provided in the pricing supplement and will not be less than 2.10.
**Reflects Upside Leverage Factor equal to the minimum Upside Leverage Factor set forth herein, for illustrative purposes.
The
“total return” as used above is the number, expressed as a percentage, that results from comparing the payment at maturity pe r
$1,000 principal amount note to $
The
hypothetical returns shown above apply only at maturity. These hypotheticals do not reflect fees or expenses that would be
associated with any sale in the secondary market. If these fees and expenses were included, the hypothetical returns shown above would
likely be lower.
J.P. Morgan Structured Investments | 1 800 576 3529 | jpm_structured_investments@jpmorgan.com
Final Value of
Lesser Performing
Underlying
Lesser Performing
Underlying Return
Total Return on
the Notes
165.00
65.00%
136.50%
150.00
50.00%
105.00%
140.00
40.00%
84.00%
130.00
30.00%
63.00%
120.00
20.00%
42.00%
110.00
10.00%
21.00%
105.00
5.00%
10.50%
100.00
0.00%
0.00%
80.00
-
20.00% 0.00%
70.00
-
30.00% 0.00%
69.99
-
30.01% -
30.01%
60.00
-
40.00% -
40.00%
40.00
-
60.00% -
60.00%
20.00
-
80.00% -
80.00%
0.00
-
100.00% -
100.00%
5
yr NKY EEM Uncapped Accelerated Barrier Notes
North America Structured Investments
Hypothetical Total Returns**

J.P. Morgan Structured Investments | 1 800 576 3529 | jpm_structured_investments@jpmorgan.com
Selected Risks
•
Your investment in the notes may result in a loss. The notes do not guarantee any return
of principal.
•
Any payment on the notes is subject to the credit risks of JPMorgan Chase Financial
Company LLC and JPMorgan Chase & Co. Therefore the value of the notes prior to
maturity will be subject to changes in the market’s view of the creditworthiness of
JPMorgan Chase Financial Company LLC or JPMorgan Chase & Co.
•
You are exposed to the risk of decline in the value of each Underlying.
•
Your payment at maturity will be determined by the Lesser Performing Underlying.
•
The benefit provided b y the Barrier Amount may terminate on the Observation Date.
•
No interest payments, dividend payments or voting rights.
•
The notes are subject to the risks associated with non U.S. securities.
•
The notes do not provide direct exposure to fluctuations in foreign exchange rates with
respect to the Index.
•
The Fund is subject to management risk.
•
The performance and market value of the Fund, particularly during periods of market
volatility, may not correlate with the performance of the Fund’s underlying index as well as
the net asset value per share.
•
The notes are subject to emerging markets risk with respect to the Fund.
•
The notes are subject to currency exchange risk with respect to the Fund.
•
Recent executive orders may adversely affect the performance of the Fund.
•
The anti dilution for the Fund is limited.
•
As a finance subsidiary, JPMorgan Chase Financial Company LLC has no independent
operations and has limited assets.
Selected Risks (continued)
•
The estimated value of the notes will be lower than the original issue price (price to public) of
the notes.
•
The estimated value of the notes is determined by reference to an internal funding rate.
•
The estimated value of the notes does not represent future values and may differ from
others’ estimates.
•
The value of the notes, which may be reflected in customer account statements, may be
higher than the then current estimated value of the notes for a limited time period.
•
Lack of liquidity: J.P. Morgan Securities LLC (who we refer to as JPMS ) intends to offer to
purchase the notes in the secondary market but is not required to do so. The price, if any, at
which JPMS will be willing to purchase notes from you in the secondary market, if at all, may
result in a significant loss of your principal.
•
Potential conflicts: We and our affiliates play a variety of roles in connection with the
issuance of notes, including acting as calculation agent and hedging our obligations under
the notes, and making the assumptions used to determine the pricing of the notes and the
estimated value of the notes when the terms of the notes are set. It is possible that such
hedging or other trading activities of J.P. Morgan or its affiliates could result in substantial
returns for J.P. Morgan and its affiliates while the value of the notes decline.
•
The tax consequences of the notes may be uncertain. You should consult your tax adviser
regarding the U.S. federal income tax consequences of an investment in the notes .
..
Additional Information
SEC Legend: JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. have filed a registration statement (including a pr
osp ectus) with the SEC for any offerings to which these materials relate. Before you
invest, you should read the prospectus in that registration statement and the other documents relating to this offering that JPM organ Chase Financial Company LLC and JPMorgan Chase & Co. has filed with the SEC for
more complete information about JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co. and this offering. You may get the se documents without cost by visiting EDGAR on the SEC web site at
www.sec.gov. Alternatively, JPMorgan Chase Financial Company LLC and JPMorgan Chase & Co., any agent or any dealer participating in the this offering will arrange to send you the pr ospectus and each prospectus
supplement as well as any product supplement, underlying supplement and preliminary pricing supplement if you so request by calling toll free 1 866 535 9248.
IRS Circular 230 Disclosure: JPMorgan Chase & Co. and its affiliates do not provide tax advice. Accordingly, any discussion o
f U .S. tax matters contained herein (including any attachments) is not intended or written to be
used, and cannot be used, in connection with the promotion, marketing or recommendation by anyone unaffiliated with JPMorgan Cha se & Co. of any of the matters addressed herein or for the purpose of avoiding U.S.
tax related penalties.
Investment suitability must be determined individually for each investor, and the financial instruments described herein may
not be suitable for all investors. This information is not intended to provide and should not be
relied upon as providing accounting, legal, regulatory or tax advice. Investors should consult with their own advisers as to these matters.
This material is not a product of J.P. Morgan Research Departments
Free Writing Prospectus Filed Pursuant to Rule 433,
Registration Statement Nos. 333 236659 and 333 236659 01
North America Structured Investments
5yr
NKY EEM Uncapped Accelerated Barrier Notes
The risks identified above are not exhaustive. Please see “Risk Factors” in the
prospectus supplement and the applicable product supplement and underlying supplement and
“Selected Risk Considerations” in the applicable preliminary pricing supplement for additional information